Sermersheim, Matthew http://orcid.org/0000-0003-3252-0986
Kenney, Adam D.
Lin, Pei-Hui http://orcid.org/0000-0002-3894-5099
McMichael, Temet M.
Cai, Chuanxi http://orcid.org/0000-0003-0532-7435
Gumpper, Kristyn http://orcid.org/0000-0003-2704-1868
Adesanya, T. M. Ayodele http://orcid.org/0000-0002-3897-2468
Li, Haichang
Zhou, Xinyu http://orcid.org/0000-0002-1606-5816
Park, Ki-Ho http://orcid.org/0000-0002-6193-9826
Yount, Jacob S.
Ma, Jianjie http://orcid.org/0000-0003-3865-6112
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR061385, AR070752)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK106394)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL138570)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI130110, AI142256)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM068412)
Article History
Received: 8 October 2019
Accepted: 2 June 2020
First Online: 17 July 2020
Competing interests
: J.M. has an equity interest in TRIM-edicine, which develops MG53 for the treatment of human disease. Patents on the use of MG53 are held by Rutgers University Robert Wood Johnson Medical School. All other authors confirm no other conflicts of interest.